A team of researchers has found that an antidepressant called tranylcypromine (TCP) can harness the power of a vitamin A-derivative to treat acute myeloid leukemia (AML). The study reveals that inhibiting an enzyme called LSD1 with TCP can switch genes on, making cancer cells susceptible to ATRA.
The foundation awarded individual grants to six new researchers and funded 18 collaborative grants, totaling over $3.1 million. The grants focus on reprogramming enzymes and genes into therapies to eradicate cancer stem cells.
The Max Cure Foundation and Samuel Waxman Cancer Research Foundation have partnered to fund research targeting the Ewing sarcoma family of tumors. Erwin G. Van Meir's proposal aims to reprogram ESFT cancer stem cells using a small molecule that induces cell death.
Scientists have identified a drug combination that shows a survival advantage in advanced lung cancer patients who no longer respond to existing therapies. The combination of bexarotene and erlotinib broadens the reach to include patients resistant due to ras mutations, offering new hope for those with limited treatment options.
The Samuel Waxman Cancer Research Foundation has awarded 13 collaborative and 3 individual research grants worth $1.54 million to top scientists exploring cancer differentiation therapy. The recipients are experts in reprogramming cancer cells, with a focus on finding new treatments for various types of cancer.
Researchers have successfully induced epigenetic reprogramming in human and mouse breast cancer cells, making them more susceptible to tamoxifen treatment. This targeted epigenetic therapy has shown promising results in reversing the growth and invasive properties of triple-negative breast cancer cells.
Researchers have developed a new type of drug that targets the BCL6 protein, which is essential for lymphoma cell survival and multiplication. The breakthrough could lead to improved treatment options with fewer side effects, increasing cure rates for diffuse large B cell lymphomas.
Molecular biologist Alan Ashworth will receive a $50,000 grant from the Samuel Waxman Cancer Research Foundation to study PARP inhibitors in BRCA-mutated cancers. His research aims to develop novel treatments for triple-negative breast cancer and other related cancers.